A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
Browsing: non-small-cell lung cancer
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
AstraZeneca and MedImmune have announced results of their Phase III PACIFIC trial.
Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).
What advancements have we witnessed in the field of immunotherapy for lung cancer and what does the future of this field look like? Find out in this article from Lung Cancer Management.
News round-up: Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed
Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed.
Phase III IM power150 study has demonstrated that atezolizumab and bevacizumab plus carboplatin and paclitaxel helped individuals with advanced lung cancer live longer compared to avastin plus carboplatin and paclitaxel.
AstraZeneca’s novel immunotherapy for non-small cell lung cancer has been authorized for use by the FDA.